期刊文献+

肝硬化患者血浆氧化型低密度脂蛋白测定 被引量:2

Determination of Plasma Ox-LDL in patients with liver Cirrhosis
暂未订购
导出
摘要 本研究应用酶联免疫吸附法对肝硬化患者血浆氧化型低密度脂蛋白(Ox - LDL) 进行测定。结果表明:正常对照组,肝硬化代偿期组和肝硬化失代偿期组血清Ox - LDL 分别为(420 .7±112 .1)μg/L、(634 .1 ±167 .3)μg/L和(716 .3 ±259.5)μg/L,后两组与正常对照组比较差异均有显著性( P< 0 .01) 。肝硬化失代偿期患者Ox - LDL与ALT 及胆红素呈正相关( P< 0.05)与白蛋白呈负相关( P< 0 .05) 。结果提示Ox - LDL 是肝硬化发展过程中至肝损害的因素之一。Ox- LDL测定对肝硬化的病情判断有一定意义。 Oxidized low density lipoprotein(Ox-LDL) was mesured by ELISA in 41 patients with cirrhosis and 16 healthy controls.The results showed that the plasma Ox-LDL were 420.7±112.1μg/L in healthy controls,634.1±167.3μg/L in compensation cirrhosis and 716.1±259.5 μg/L in uncompensation cirrhosis.The Ox-LDL of the two cirrhosis groups were higher than that of control (P<0.01).The pasitive correlation between the level of Ox-LDL and the level of ALT and bilirubin was observed (P<0.05).Negative correlation between the level of Ox-LDL and the level of albumin was observed (P<0.05).The results suggest that the Ox-LDL might play as an in jury factor in the pathogenesis of cirrhosis.The measurement of Ox-LDL should be useful in the assessment of severity for cirrhosis.
出处 《临床肝胆病杂志》 CAS 北大核心 1999年第4期243-245,共3页 Journal of Clinical Hepatology
关键词 肝硬化 测定 OX-LDL ELISA Cirrhosis Oxidized Low density lipoprotin ELISA
  • 相关文献

同被引文献31

  • 1张群伟,刘红军,段海峰,哈小琴,王华,贾向旭,鲁茁壮,吴祖泽,王立生.肝细胞生长因子对骨髓内皮祖细胞的动员作用[J].中国应用生理学杂志,2005,21(1):100-103. 被引量:7
  • 2McLean JW, Tomlinson JW,Kuang WJ, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen [ J ]. Na- ture, 1987, 330(6144) :132-137.
  • 3Koschinsky ML. Novel insights into Lp(a) physiology and patho- genicity: more questions than answers [ J ]. Cardiovasc Hematol Disord Drug Targets,2006, 6(4) : 267-278.
  • 4Van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apoli- poprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms[ J]. Hum Mol Gen- et, 1993, 2(4) :361-366.
  • 5Lackner C, Cohen JC, Hobbs HH. Molecular definition of the ex-treme size polymorphism in apolipoprotein(a) [ J]. Hum Mol Gen- et, 1993, 2(7): 933-940.
  • 6Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentra- tion and the risk of coronary heart disease, stroke, and nonvascular mortality[J]. JAMA, 2009, 302(4) : 412-423.
  • 7Seanu AM,Lawn RM, Berg K. Lipoprotein (a) and atheroselerosis [J]. AnnlntemMed,1991,115(3): 209-218.
  • 8Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associ- ated with Lp(a) lipoprotein level and coronary disease[ J]. N En- gl J Med, 2009, 361(26): 2518-2528.
  • 9Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymor- phisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans[J]. PLoS One, 2011, 6 (1) : e14581.
  • 10Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apolipoprotein ( a ) kringle 4 domains on immunochemical measurements of lipoprotein (a) [ J]. Clin Chem, 1995, 41 (2) : 246-255.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部